gutflix
GI learning, personalised

Summary

# USTEKINUMAB PROMOTES RADIOLOGICAL FISTULA HEALING IN PERIANAL FISTULIZING CROHN'S DISEASE:RETROSPECTIVE REAL-WORLD ANALYSIS

Mehmet Ali Şahan

UEG Week Vienna 2024 | Poster

IBD

October 13, 2024

**Retrospective real-world study of 17 Crohn's disease patients with perianal fistula found 40% achieved fistula closure after approximately 59 weeks of ustekinumab therapy.**

KEY POINTS

- After 58.66 ± 13.48 weeks of ustekinumab therapy, fistula closure was shown in 40% (6 of 17) of patients with perianal fistulizing Crohn's disease.
- Most fistulas were inter-sphincteric (65%), and patients had a mean disease duration of 3.4 ± 0.6 years.
- No significant difference in fistula closure was detected between patients with and without endoscopic remission at 6 months (57.1% vs 42.9%, p=0.315).
- The authors conclude that intestinal endoscopic remission may not be correlated with fistula outcome and further research is needed to determine ustekinumab efficacy for perianal fistula.
- This retrospective analysis used MRI to assess radiological fistula outcomes and may be relevant to gastroenterologists managing perianal fistulizing Crohn's disease patients.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/0804d9e4-9112-11ef-930d-0242ac140004

**AI-generated summary**

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.